The 1p/19q status is a critical molecular marker for subclassifying isocitrate dehydrogenase(IDH)-mutant adult diffuse gliomas and plays a pivotal role in prognostication and therapeutic decision-making [1–3]. However, pathology-based determination is inherently delayed, failing to provide timely guidance prior to invasive diagnostic procedures.

Read the full article on ejradiology.com